Kyowa Kirin to acquire Orchard Therapeutics in deal worth $477m
The deal gives Kyowa access to a therapy for early-onset metachromatic leukodystrophy
Read More
Tag: Kyowa Kirin
NICE to reassess Kyowa Kirin’s Poteligeo
An appeal lodged by the company and various charities has been upheld by an independent appeal panel
Read More
NICE rejects rare blood cancer treatment Poteligeo in final appraisal
Final appraisal document said that clinical trial evidence for Poteligeo is ‘very uncertain’
Read More
Kyowa Kirin’s Crysvita wins EU approval for expanded XLH population
New approval includes older adolescents and adults with rare disease
Read More
NICE rejects NHS funding for Kyowa Kirin’s Poteligeo
NICE is not recommending NHS funding for Kyowa Kirin’s Poteligeo (mogamulizumab) as a treatment for mycosis fungoides or Sézary syndrome for adults who have had at least one previous systemic treatment.
Read More
CHMP backs expanding scope of Kyowa Kirin’s Crysvita
The decision could see older adolescents and adults access the treatment for X-linked hypophosphataemia (XLH)
Read More
Rare disease therapy Crysvita to be barred from NHS
Children and young people with X-linked hypophosphataemia (XLH) are unlikely to get routine access to Kyowa Kirin’s Crysvita on the NHS.
Read More
EU clears rare musculoskeletal disorder drug
Doctors can now treat children living in the EU with the rare, chronic progressive musculoskeletal disorder X–Linked Hypophosphataemia with Kyowa Kirin/Ultragenyx’ Crysvita following its conditional approval in the region.
Read More
Seven therapies backed for EU approval
Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
